Insulin mutations impair beta-cell development in a patient-derived iPSC model of neonatal diabetes
Year: 2018
Type: article
Abstract: Insulin gene mutations are a leading cause of neonatal diabetes. They can lead to proinsulin misfolding and its retention in endoplasmic reticulum (ER). This results in increased ER-stress suggested to trigger beta-cell apoptosis. In humans, the mechanisms underlying beta-cell failure remain unclear. Here we show that misfolded proinsulin impairs developing beta-cell proliferation without increasing apoptosis. We generated induced pluripotent stem cells (iPSCs) from people carrying insulin (INS) mutations, engineered isogenic CRISPR-Cas9 mutation-corrected lines and differentiated them to beta-like cells. Single-cell RNA-sequencing analysis showed increased ER-stress and reduced proliferation in INS-mutant beta-like cells compared with corrected controls. Upon transplantation into mice, INS-mutant grafts presented reduced insulin secretion and aggravated ER-stress. Cell size, mTORC1 signaling, and respiratory chain subunits expression were all reduced in INS-mutant beta-like cells, yet apoptosis was not increased at any stage. Our results demonstrate that neonatal diabetes-associated INS-mutations lead to defective beta-cell mass expansion, contributing to diabetes development.
Source: eLife
DOI: 10.7554/elife.38519
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: insulin gene mutations, neonatal diabetes, beta-cell development, proinsulin misfolding, endoplasmic reticulum stress, beta-cell proliferation, beta-cell mass expansion, induced pluripotent stem cells, CRISPR/Cas9 gene correction, beta-like cells, mTORC1 signaling, islet transplantation, single-cell RNA sequencing
Open Access status: gold
Estimated APC paid: $2,500
Funders: Leona M. and Harry B. Helmsley Charitable Trust, Helsingin Yliopisto, Maud Kuistilan Muistosäätiö, European Federation of Pharmaceutical Industries and Associations, Diabetes Research and Wellness Foundation, European Commission, Academy of Finland, Biomedicum Helsinki-säätiö, Novo Nordisk, Sigrid Juséliuksen Säätiö, Diabetesliitto, Novo Nordisk Fonden, Innovative Medicines Initiative
OpenAlex ID: W2899546454
